New Orleans, LANCT06610201Now EnrollingIRB Ready

Von Willebrand Disease (VWD) Clinical Trial in New Orleans, LA

Access cutting-edge von willebrand disease (vwd) treatment through this clinical trial at a research site in New Orleans. Study-provided care at no cost to qualified participants.

Sponsored by Hemab ApS

Quick Self-Assessment

See if you qualify for this New Orleans location

Preparing your pre-screening questions…

Expert Care in New Orleans

Access von willebrand disease (vwd) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related von willebrand disease (vwd) treatment provided free

Apply for This New Orleans Location

Check if you qualify for this von willebrand disease (vwd) clinical trial in New Orleans, LA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Orleans

    Convenient for LA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Orleans site if eligible
  4. 4Begin participation

About This Von Willebrand Disease (VWD) Study in New Orleans

The purpose of this screening study is to accumulate information regarding bleeding events, quality of life, and the social and clinical impact of bleeds in participants with Von Willebrand Disease (VWD). Data from this study will be used to establish baseline bleeding and treatment rates in a population of participants with VWD and act as comparator data for future clinical study outcomes.(e.g. Velora Pioneer)

Sponsor: Hemab ApS

Who Can Participate

Inclusion Criteria

Has the ability to provide informed consent to participate in the study, in accordance with applicable regulations.
Has an understanding, ability, and willingness to comply with Study procedures and restrictions.
Is 16 years and \< 70 years at the time of screening.
Weight 50 to 120 kg (±10%) at Screening and body mass index (BMI) \<38.5 kg/m\*2.
Has Von Willebrand Disease: Type 1 VWD (including Type 1C VWD) or Type 2A VWD. All participants must have: Documented lab results confirming their diagnosis consistent with ISTH/ASH diagnostic guidelines; VWF Activity ≤30 IU/dL and FVIII activity ≤70 IU/dL during Screening.
Has symptomatic disease as defined by a history of bruising or bleeding events, with an expected minimum of 3 bleeding episodes (including heavy menstrual bleeding) per year that require treatment to control bleeding symptoms, and/or has recurrent and ongoing episodes of heavy menstrual bleeding at the time of enrollment.

Exclusion Criteria

Has a history of clinically significant hypersensitivity associated with monoclonal antibody therapies.
Has a personal history of venous or arterial thrombosis or thromboembolic disease, except for catheter-associated, superficial vein thrombosis events.
Has a high-risk thrombophilia: Homozygous Factor V Leiden (FVL), compound heterozygous FVL/prothrombin gene mutation, antithrombin \<50%, congenital protein C and protein S deficiency with levels \<50%.
Requires ongoing hemostatic (bleed-prophylaxis) treatment to prevent bleeding
Has other known severe bleeding disorder(s) other than VWD.
Planned major surgery during the study period.
Has other conditions that substantially increase the risk of thrombosis either individually or in combination, at the discretion of the Investigator, including but not limited to: significant family history; BMI \>30 and ≤38.5 kg/m² (moderately obese, adjusted for ethnicity and increased central adiposity); reduced mobility; active malignancy; major surgery within 6 weeks preceding Screening; or postpartum within 12 weeks preceding Screening.
Is pregnant or plans to become pregnant within the next 6 months following informed consent sign off.
Has clinically significant cardiovascular disease including, but not limited to: NYHA Class III or IV heart failure, coronary artery disease, uncontrolled arrythmia, moderate to severe valvular heart disease, peripheral vascular disease, and ischemic stroke.
Has other combinations of conditions that substantially increase the risk of cardiovascular events at the discretion of the Investigator including, but not limited to, smoking, uncontrolled hyperlipidemia, and uncontrolled hypertension.
Has any concurrent disease, treatment, medication (including but not limited to ongoing anticoagulation, antiplatelet therapy, or non-steroidal anti-inflammatory drugs or other drugs that affect hemostasis), condition, medication, or abnormality in clinical laboratory tests which may impact on the participant's bleeding symptoms or affect their ability to complete the study, in the Investigator's opinion.
Has received any investigational product within 30 days prior to Screening. If the participant was enrolled and dosed in Velora Pioneer (study HMB-002-102; NCT06754852), they must have completed their End of Study Visit.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Orleans?

Yes, this clinical trial (NCT06610201) has an active research site in New Orleans, LA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Von Willebrand Disease (VWD) Treatment Options in New Orleans, LA

If you're searching for von willebrand disease (vwd) treatment options in New Orleans, LA, this clinical trial (NCT06610201) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Orleans research site is actively enrolling participants for this clinical trial. You'll receive care from experienced von willebrand disease (vwd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all von willebrand disease (vwd) clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in New Orleans, LA

See all rheumatoid arthritis clinical trials recruiting in New Orleans — not just this study.

Browse Rheumatoid Arthritis Trials in New Orleans →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsVon Willebrand Disease TrialsAll Conditions →

Ready to Join in New Orleans?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Orleans, LA